TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Male or female subjects aged greater than and equal to (\>=) 12 years at the screening visit.~* Chronic atopic dermatitis (according to American Academy of Dermatology Consensus Criteria) that has been present for at least 2 years before the screening visit.~* Eczema Area and Severity Index (EASI) score \>=16 at the screening and baseline visits.~* Investigator Global Assessment (IGA) score \>= 3 (scale of 0 to 4) at the screening and baseline visits.~* AD involvement \>= 10 percent (%) of body surface area (BSA) at screening and baseline visits.~* Peak Pruritus Numerical Rating Scale (PPNRS) score of at least 4.0 at the screening and baseline visit.~* Documented recent history of inadequate response to topical medications (topical corticosteroids \[TCS\] with or without Topical calcineurin inhibitors \[TCI\]).~* Female subjects of childbearing potential (that is, fertile, following menarche and until becoming postmenopausal unless permanently sterile) must agree either to be strictly abstinent throughout the study and for 12 weeks after the last study drug injection, or to use an adequate and approved method of contraception throughout the study and for 12 weeks after the last study drug injection.~Key Exclusion Criteria:~* Body weight (\<) 30 kilograms (kg).~* Exacerbation of asthma requiring hospitalization in the preceding 12 months. Uncontrolled asthma in the preceding 3 months.~* Cutaneous infection within 1 week before the baseline visit, any infection requiring treatment with oral or parenteral antibiotics, antivirals, antiparasitics or antifungals within 2 weeks before the baseline visit, or any confirmed or suspected coronavirus disease (COVID)-19 infection within 2 weeks before the screening or baseline visit.~* Pregnant women, breastfeeding women, or women planning a pregnancy during the clinical study.~Note: Subjects with chronic, stable use of prophylactic treatment for recurrent herpes viral infection can be included in this clinical study.~* History of hypersensitivity (including anaphylaxis) to an immunoglobulin product (plasma-derived or recombinant, example, monoclonal antibody) or to any of the study drug excipients.~* Any clinically significant issue, based on investigator judgement.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo
- Nemolizumab (Type: EXPERIMENTAL): Nemolizumab Active

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: BIBR 1048 Dose Range Finding Study in Prevention of Venous Thromboembolism in Patients With Primary Elective Total Hip or Knee Replacement Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion criteria~1. Patients scheduled to undergo a primary elective total hip or knee replacement.~2. Male of female being 18 years or older.~3. Patients weighing at least 40 kg.~4. Written informed consent for study participation.~Exclusion criteria~1. Bleeding diathesis, constitutional or acquired coagulation disorders.~2. Major surgery or trauma(e.g., hip fracture) within the last 3 months.~3. Cardiovascular disease~4. Any history of haemorrhagic stroke, intracranial or intraocular bleeding or cerebral ischaemic attacks lasting more than 24 hours and / or with cardiovascular pathological findings.~5. Deep vein thrombosis(DVT), gastrointestinal or pulmonary bleeding, gastric or duodenal ulcer within the last year.~6. History of or acute intracranial disease~7. Liver disease~8. Renal disease~9. Use of long-term anticoagulants or antiplatelet drugs within 7 days prior to hip/knee replacement operation.~10. Pre-menopausal women who are not surgically steriles, are nursing and are of child-bearing potential and are not practising acceptable methods of birth control~11. Known allergy to contrast media~12. Thrombocytopenia~13. Allergy against heparin.~14. Active malignant disease or current cytostatic treatment.~15. Treatment with an investigational drug in the past month.~16. Leg amputee~17. Known alcohol or drug abuse

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BIBR 1048 50 mg bis in die(b.i.d) (Type: EXPERIMENTAL): BIBR 1048 50 mg b.i.d twice a day plus two capsules of placebo matching BIBR 1048 0 mg twice a day plus one placebo matching enoxaparin 0 mg once a day for the treatment period
- BIBR 1048 150 mg b.i.d (Type: EXPERIMENTAL): BIBR 1048 150 mg b.i.d twice a day plus two capsules of placebo matching BIBR 1048 0 mg twice a day plus placebo matching enoxaparin 0 mg once a day for the treatment period
- BIBR 1048 225 mg b.i.d (Type: EXPERIMENTAL): BIBR 1048 225 mg b.i.d twice a day plus two capsules of placebo matching BIBR 1048 0 mg twice a day plus placebo matching enoxaparin 0 mg once a day for the treatment period
- BIBR 1048 300 mg quaque die(q.d) (Type: EXPERIMENTAL): BIBR 1048 150 mg q.d once a day plus placebo matching BIBR 1048 0 mg twice a day plus placebo matching enoxaparin 0 mg once a day for the treatment period
- Enoxaparin 40 mg subcutaneous(s.c) (Type: ACTIVE_COMPARATOR): placebo matching BIBR 1048 0 mg twice a day plus enoxaparin 40 mg s.c once a day for the treatment period

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ultrasound Elastography of Breast Lesions

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* patients who have been referred to a breast ultrasound because of a positive physical palpation and/or positive mammograms and/or positive ultrasound and/or positive MRI.~* female~* age 21 or older~* provide informed consent~Exclusion Criteria:~* Women who are unwilling or unable to provide informed consent~* Women with breast implants~* Women with superficial lesions or lesions on skin (with the most superficial surface of the lesion within 5 mm of the skin surface)~* Women who are pregnant or breastfeeding~* Women who are undergoing chemotherapy or radiotherapy for any cancer~* Women with previous breast conserving surgery on the breast of interest Note: Previous excision of a benign lesion 4 cm or more away from the suspected lesion does not constitute an exclusion criterion.

- Gender: FEMALE
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Infliximab in Patients With Sarcoidosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients must have been diagnosed with sarcoidosis at least 1 year prior to entry into the study~* Patients must have laboratory test diagnosing sarcoidosis prior to screening~* Patients must have a diagnosis of sarcoidosis by chest x- ray~Exclusion Criteria:~* Patients must not have used any investigational drug within 1 month prior to entering the study~* Patients must not have received previous administration of a treatment with any other therapeutic agent targeted at reducing TNF such as pentoxifylline, thalidomide, etanercept, CDP 870, adalimumab, within 3 months prior to screening~* Patients must not have received vaccinations within 3 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pilot Trial: Postoperative Opioid-free Analgesia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Adult patients (\>18 yo) undergoing outpatient surgery~* Abdominal surgery (i.e. cholecystectomies, hernia repairs, ovarian cystectomies, salpingectomies)~* Breast surgery (i.e. lumpectomies, partial and complete mastectomies, axillary node dissections)~Exclusion Criteria:~All patients~* Intraoperative or early postoperative complications (i.e. diagnosed in the Post-Anesthesia Care Unit (PACU)) that require postoperative hospital stay~* Contraindications to any of the drugs used in the trial~* Difficult to be reached after surgery~* Inability to provide written informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Opioid analgesia (Type: EXPERIMENTAL): None
- Opioid-free analgesia (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect and Safety Study of GP/FP Regimens in Advanced Nasopharyngeal Carcinoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically proven NPC diagnosis~* Elder than 18 years old are inclusive~* Recurrence or metastatic nasopharyngeal carcinoma with evidence of unsuitable for local treatment~* Amenable to regular follow-up~* Subjects with at least one measurable lesion (Tumor lesions that are situated in a previously irradiated area could not be considered measurable).~* Performance status: 0-1(ECOG)~* WBC \> 4.0X109/L, PLT \> 100X109/L, with normal hepatic function(AST, ALT \< 2.5 x upper limit of normal , and bilirubin \< 1.5 x upper limit of normal), with normal renal function (Creatinine \< 1.5 x upper limit of normal)~* No chemotherapy or radical radiotherapy received within 6 months prior to enrollment~* Life expectancy over twelve weeks~* Signed and dated informed consent before the start of specific protocol procedures~* Ability to comply with trial requirements.~Exclusion Criteria:~* Patient suitable for local treatment (eg. radiotherapy)~* Active clinically serious infections (\> grade 2 NCI-CTC version 3.0)~* Patient with central nervous system metastasis~* Patient life threatening medical condition~* Pregnant or breast-feeding patients. Women of childbearing potential must have a negative pregnancy test performed within 7 days of the start of treatment. Both men and women enrolled in this trial must use adequate barrier birth control measures during the course of the trial and two weeks after the completion of trial.~* Performance status ≥ 2~* With a pre-existing peripheral neuropathy (National Cancer Institute Common Toxicity Criteria for Adverse Events \[NCI CTC\] grade ≥ 2)~* Serious concurrent illness~* Previous or concurrent cancer that is distinct in primary site or histology from the cancer being evaluated in this study EXCEPT cervical carcinoma in situ, treated basal cell carcinoma, superficial bladder tumors\[Ta, Tis \& T1\] or any cancer curatively treated \> 3 years prior to study entry.~* Patient refusing participation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- gemcitabine and cisplatin (Type: EXPERIMENTAL): gemcitabine 1,000 mg/m2 over 30 to 60 minutes on days 1, 8, and plus cisplatin 80 mg/m2 on day 1, every 3 weeks.
- 5-Fluorouracil and cisplatin (Type: ACTIVE_COMPARATOR): 5-Fluorouracil 4,000 mg/m2 CIV over 96 hours and plus cisplatin 80 mg/m2 on day 1, every 3 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Previously Untreated Marginal Zone Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* ≥ 18 years old with previously untreated, histologically confirmed Marginal Zone Lymphoma (non-gastric extranodal MZL, splenic MZL and nodal MZL) or gastric MZL that did not respond to antibiotic therapy given up to 6 months prior to enrollment, but not less than 2 months)~* Measurable and evaluable disease~* All stages are eligible~* Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1, or 2 (Appendix B)~* Willing and able to provide written informed consent~* Women of childbearing potential must have a negative pregnancy test at study entry and must agree to use effective contraception while on treatment and for 6 months after treatment~* Life expectancy of at least 6 months~Exclusion Criteria:~* Prior chemotherapy, radiation therapy, immunotherapy, systemic corticosteroids, or systemic biologic anticancer therapy before beginning study treatment.~* ≥ 25% lymphoma bone marrow involvement~* Platelet count \< 100,000 cells/mm³~* Neutrophil count \< 1,500 cells/mm³~* Known history of HIV infection~* Pregnant or lactating (pregnancy test is required for all female patients of childbearing potential)~* Woman of childbearing potential or sexually active man unwilling to use adequate contraceptive protection.~* Physical or mental condition that makes patient unable to complete specified follow-up assessments

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Zevalin + Rituximab (Type: EXPERIMENTAL): Ibritumomab Tiuxetan (Zevalin) + Rituximab

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Transfusion Savings in Heart Surgery: Impact of Individual Strategy by Erythropoietin and Metabolic Adjustment (ScvO2)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Scheduled Cardiac surgery for more than 24 hours~* High risk of perioperative transfusion defined by a TRUST Score ≥ 3~* Veno-Venous catheter in Superior vena cava territory~* Patient Affiliate or beneficiary of social security~* Collection on free, informed and written consent~Exclusion Criteria:~* EPO and FCM contraindication~* Patients already treated by EPO at the time of inclusion~* Non controlled Infectious endocarditis defined by ESC guidelines 2015~* Patients including in an other research~* Patients whose physical and/or psychological health is severely impaired and who, according to the investigator, may affect the participant's compliance with the study.~* Patients deprived from his rights (guardianship or tutelage measure)~* Patients who refuses to sign the consent~* pregnant or lactating woman

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- STOP Group (Type: EXPERIMENTAL): EPO (600UI/Kg, sub-cutaneous) and Ferric Carboxymaltose (FCM) (20 mg/kg in 250 mL of saline solution 0.9% over 15 min) will be administered if~* Hb \< 13g/dL the day before surgery~* Hb ≥ 7g/dL AND ScvO2 \> 65% in postoperative ICU stay~Postoperative Transfusion will be guided by ScvO2 values :~if Hb ≤ 8 g/dL AND ScvO2 ≤ 65% or if Hb \< 7g/dL independently of ScVO2 value
- Control Group (Type: NO_INTERVENTION): Only postoperative anemia will be managed:~* RBC transfusion will be performed if Hb ≤ 8 g/dL (2017 EACTS/EACTA guidelines)~* Iron sucrose administration if Hb \> 8g/dL : 2 injections of 200 mg according to Height (+/- 70 Kg) in 250 mL of saline solution 0.9% over 1h30 into 48 h intervals without exceeding a total dose of 15mg/kg.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Intensive Lipid Lowering Treatment Compared to Moderate Lipid Lowering Treatment on Endothelial Function

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. STEMI~2. no prior treatment with statins~Exclusion Criteria:~1. age below 18 or above 81 years~2. unconscious patients~3. serum creatinine \> 176μmol/L~4. total-cholesterol \> 7.0 mmol/l~5. hypothyreoidism ((TSH \> 1.5 x ULN (upper limit of normal))~6. current liver disease (ALAT \> 2 x ULN)~7. unexplained creatine kinase \> 3 x ULN~8. alcohol or drug abuse within the last five years~9. prior myopathy or serious hypersensitivity reaction caused by statins~10. women with childbearing potential who were not using chemical or mechanical contraception~11. pregnant or breastfeeding women~12. history of malignancy unless a disease-free period of more than five years was present~13. patients with abnormal lung function test (LFT)~14. participation in another investigational drug study less than four weeks before enrolment in the present study~15. treatment with cyclosporine or fibrates.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 81 Years
- Healthy Volunteers: f

Study Arms:
- Rosuvastatin 5mg/day (Type: ACTIVE_COMPARATOR): Rosuvastatin 5mg/day
- Rosuvastatin 40mg/day (Type: ACTIVE_COMPARATOR): Rosuvastatin 40mg/day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Drug Interaction Study With BI 201335 and Methadone or Buprenorphine/Naloxone

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~1. stable dose of either methadone or buprenorphine/naloxone for 30 days for opioid maintenance therapy.~2. Male and female volunteers with a body mass index (BMI) = 18.5 and \< 32 with a minimum weight of 50kg.~Exclusion criteria:~1. any other significant medical illness of clinical significance.~2. history of rash or photosensitivity~3. chronic or acute infections including HIV, hepatitis B and hepatitis C.~4. history of allergy considered significant for this study~5. intake of any other medications except for methadone or buprenorphine/naloxone.~6. QTc on electrocardiogram (ECG) \> 470.~7. use of any other investigational drug within 30 days of the study.~8. drug or alcohol abuse (other than the defined opioid maintenance therapy with either methadone or buprenorphine/naloxone)~9. blood donation of more than 100mL within four weeks of the trial.~10. excessive physical activities one week prior to and during the trial.~11. any clinically relevant laboratory value.~12. concomitant use of any food product known to alter P450 or P-gp activity such as grapefruit juice, seville oranges and St. John's Wort.~13. inadequate venous access~    For women of childbearing potential:~14. pregnancy or planning to become pregnant within 3 months of the trial~15. positive pregnancy test at screening visit~16. no proof of sterilization or unwilling or unable to use a double barrier method of birth control during the study and up to 3 months after the study.~17. lactation with active breastfeeding from screening up to 30 days after last study visit.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- Methadone group (Type: ACTIVE_COMPARATOR): patients on stable methadone therapy (at least 30 days) up to a maximum of 180mg per day
- Buprenorphine (Type: ACTIVE_COMPARATOR): patients on stable buprenorphine/naloxone therapy (at least 30 days) up to a maximum dose of 24mg/6mg per day.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete